NICE rejects Zytiga as prostate cancer treatment before chemotherapy

In its final draft guidance, NICE has not recommended abiraterone for prostate cancer in people who received hormone therapy (androgen deprivation) but whose disease has spread, who have few symptoms and when chemotherapy would not yet have been given.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Tags: *** Editor's Pick Oncology abiraterone janssen Latest News nice prostate cancer Zytiga Source Type: news